Aktualne strategie leczenia dyslipidemii w prewencji chorób układu krążenia w 2019 roku w świetle zaleceń europejskich i amerykańskich towarzystw naukowych

Disorders of lipid metabolism are the most common modifiable risk factor of cardiovascular disease, which in turn is the most common cause of death in highly developed countries. Recent studies on PSCK9 inhibitors: FOURIER and ODYSSEY OUTCOMES trials, demonstrated that lowering LDL-C level below the value recommended to date is associated with improved prognosis in CVD patients. These results were acknowledged in Polish Recommendation for the management of dyslipidemia in Poland e.g. III Declaration of Sopot. Interdisciplinary Expert Position Statementon the Cardiovascular Pharmacotherapy as well as in American 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA Guideline on the Management of Blood cholesterol, both published in 2018. Unfortunately, in spite of expert opinions and therapeutical advances, still too few patients meet the target LDL-C levels. More rigorous implementation of recent recommendations in daily clinical practice should improve CVD outcomes.